A method for limiting the growth of cancer cells using an attenuated measles virus 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO200223994 A1 2002-03-28 [WO200223994] / 2002-03-28
申请号/申请日
2001WO-US42259 / 2001-09-21
发明人
RUSSELL STEPHEN JAMES;FIELDING ADELE;PENG KAH-WHYE;GROTE DEANNA;
申请人
MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH;
主分类号
IPC分类号
A61K-035/76A61P-035/00
摘要
(WO200223994) A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus.  In one embodiment, the therapeutically effective dose is from about 10<3> pfus to about 10<12> pfus and is delivered by direct injection into a group of cancer cells or via intravenous injection.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2000US-09668196 2000-09-22
主权利要求
(WO200223994) What is claimed is: Claims 1. A method of treating cancer, comprising administering a therapeutically effective dose of attenuated measles virus to a patient so as to reduce the number of cancer cells in the patient. 2. The method of claim 1, wherein said attenuated measles virus is administered directly to said cancer cells. 3. The method of claim 1 , wherein said cancer cells are part of a tumor. 4. The method of claim 3, wherein said attenuated measles virus is injected directed into said tumor. 5. The method of claim 4, wherein said therapeutically effective dose of attenuated measles virus is provided in a formulation comprising an excipient, and said formulation is implanted in proximity to, or within, said tumor. 6. The method of claim 5, wherein said therapeutically effective dose is provided continuously to said patient. 7. The method of claim 5, wherein said therapeutically effective dose is provided in pulses to said patient. 8. The method of claim 1, wherein said therapeutically effective dose is administered systemically to a patient by intravenous injection. 9. The method of claim 1, wherein said therapeutically effective dose is administered systemically to a patient intravenously to a patient through a medical access device. 10. The method of any of claims 1-10, wherein said therapeutically effective dose is a dose of about 103to about 1012pfu. 11. The method of any of claims 1-9, wherein said therapeutically effective dose is greater than about 103pfu. 12. The method of claim 11, wherein said therapeutically effective dose is about 105pfus. 13. The method of claim 11 , wherein said therapeutically effective dose is about 106pfus. n 14. The method of claim 11 , wherein said therapeutically effective dose is about 10 pfus. 15. The method of claim 11 , wherein said therapeutically effective dose is about 108pfus. 16. The method of claim 1 , wherein said therapeutically effective dose of attenuated measles virus is provided in a composition comprising said attenuated measles virus, an attenuated mumps virus, and an attenuated rubella virus. 17. The method of claim 1 , wherein said therapeutically effective dose of attenuated measles virus is provided in a composition comprising said attenuated measles virus and an attenuated rubella virus. 18. The method of claim 1, wherein said attenuated measles virus is genetically modified to express a marker polypeptide, and wherein the expression of said marker polypeptide coπelates with the replication of said attenuated measles virus. 19. The method of claim 18, wherein said marker polypeptide is β-galactosidase or Green Fluorescent Protein. 20. The method of claim 1, wherein said cancer cells are selected from the group consisting of melanoma, carcinoma, glioma, myeloma cells, and combinations thereof. 21. The method of claim 19 wherein said myeloma cells are lymphoma cells. 22. The method of claim 21 , wherein said lymphoma cells are Non-Hodgkin' s Lymphoma cells. 23. The method of claim 1 , wherein said therapeutically effective amount of attenuated measles virus is an amount effective to cause a reduction in the number of cancer cells in a patient. 24. The method of claim 1 , wherein said attenuated measles virus is provided within a vaccine formulation. 25. The method of claim 24, wherein said vaccine is the Attenuvax® vaccine. 26. The method of claim 24, wherein said vaccine is the MMR-II vaccine. 27. The method of claim 25, wherein said vaccine is the Priorix vaccine. 28. The method of claim 1 , wherein said attenuated virus is selected from the group consisting of the Edmonston Zagreb measles strain, the Edmonston-Enders stain, the Moraten strain, and the Moraten Berna strain. 29. The method of claim 1, wherein said attenuated virus comprises a strain obtained after serial passage of a Moraten strain on non-human cells. 30. The method of claim 1, wherein said attenuated virus comprises a strain obtained after serial passage of a Edmonston strain on non-human cells. 31. The metliod of claim 1, wherein said attenuated virus comprises at least one point mutation in a wild-type or attenuated measles virus genome. 32. The method of claim 31 , wherein said attenuated virus does not comprise contiguous point mutations.
法律状态
(WO200223994) LEGAL DETAILS FOR WO200223994  Actual or expected expiration date=2004-03-22    Legal state=DEAD    Status=LAPSED     Event publication date=2001-09-21  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS0142259  Application date=2001-09-21  Standardized application number=2001WO-US42259     Event publication date=2002-03-28  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO200223994  Publication stage Code=A1  Publication date=2002-03-28  Standardized publication number=WO200223994     Event publication date=2002-03-28  Event code=WO/AL  Event indicator=Pos  Event type=Designated states  Designated countries for regional patents    Event publication date=2002-03-28  Event code=WO/AK  Event indicator=Pos  Event type=Designated states  Designated states    Event publication date=2004-03-22  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE AU9506301  Actual or expected expiration date=2007-04-02    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=AU Corresponding appl: AU9506301  Application date in the designated or member state=2001-09-21   Application number in the designated or member state=2001AU-0095063 Corresponding cc:  Designated or member state=AU Corresponding pat: AU9506301  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2002-04-02   Publication number in the designated or member state=AU200195063    Event publication date=2002-04-02  Event code=AU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2003-07-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2003-07-31  Event code=WO/REG  Event code=DE/8642  Event indicator=Neg  Event type=Non-entry into national phase  Event type=Event indicating Not In Force  Reference to a national code Impact abolished for de - i.e. PCT appl. not ent. German phase Wirkung weggefallen fuer de Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE JP  Actual or expected expiration date=2005-09-13    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=JP     Event publication date=2005-09-13  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=JP
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部